^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Voranigo (vorasidenib)

    i
    Other names: S 095032, S-095032, S 95032, S-95032, S95032, S095032, AGI-0023088, AGI-23088, AG-881, AG881, AG 881, AGI0023088, AGI 0023088, AGI23088, AGI 23088
    Company:
    Royalty, Servier
    Drug class:
    IDH1 inhibitor, IDH2 inhibitor
    Related drugs:
    Apply
    Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma (VANGUARD) (NCT07469735)
    Phase N/A
    Huashan Hospital
    Not yet recruiting
    Last update posted :
    03/13/2026
    Initiation :
    04/01/2026
    Primary completion :
    06/30/2027
    Completion :
    12/31/2027
    IDH1 • IDH2
    |
    Voranigo (vorasidenib)
    Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma (CL1-95032-005) (NCT05484622)
    Phase 1
    Institut de Recherches Internationales Servier
    Recruiting
    Last update posted :
    01/14/2025
    Initiation :
    01/20/2023
    Primary completion :
    03/31/2025
    Completion :
    08/30/2027
    IDH1 • ATRX
    |
    IDH1 R132
    |
    Keytruda (pembrolizumab) • Voranigo (vorasidenib)
    Vorasidenib Expanded Access Program (NCT05592743)
    Phase N/A
    Servier
    Available
    Last update posted :
    04/26/2024
    IDH1 • IDH2
    |
    IDH2 mutation
    |
    Voranigo (vorasidenib)
    Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation (NCT02481154)
    Phase 1
    Institut de Recherches Internationales Servier
    Active, not recruiting
    Last update posted :
    03/22/2024
    Initiation :
    06/01/2015
    Primary completion :
    10/17/2022
    Completion :
    03/01/2024
    IDH1 • IDH2
    |
    IDH1 mutation • IDH2 mutation
    |
    Voranigo (vorasidenib)
    ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas (NCT05609994)
    Phase 1
    Katy Peters, MD, PhD
    Not yet recruiting
    Last update posted :
    03/21/2024
    Initiation :
    06/01/2024
    Primary completion :
    08/01/2025
    Completion :
    08/01/2027
    IDH1
    |
    IDH1 mutation • IDH1 R132
    |
    Voranigo (vorasidenib)
    Study of AG-120 and AG-881 in Subjects With Low Grade Glioma (NCT03343197)
    Phase 1
    Institut de Recherches Internationales Servier
    Active, not recruiting
    Last update posted :
    02/26/2024
    Initiation :
    03/20/2018
    Primary completion :
    08/02/2019
    Completion :
    05/01/2025
    IDH1 • ATRX
    |
    ATRX mutation • IDH1 R132H • IDH1 R132
    |
    Tibsovo (ivosidenib) • Voranigo (vorasidenib)
    Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) (NCT04164901)
    Phase 3
    Institut de Recherches Internationales Servier
    Active, not recruiting
    Last update posted :
    12/05/2023
    Initiation :
    01/05/2020
    Primary completion :
    09/06/2022
    Completion :
    08/01/2027
    IDH1 • IDH2
    |
    IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132 • IDH2 R172
    |
    Voranigo (vorasidenib)
    Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation (NCT02492737)
    Phase 1
    Agios Pharmaceuticals, Inc.
    Completed
    Last update posted :
    03/08/2019
    Initiation :
    08/07/2015
    Primary completion :
    03/21/2018
    Completion :
    03/21/2018
    IDH1 • IDH2
    |
    IDH2 mutation
    |
    Voranigo (vorasidenib)